Overview of US Patent 8,895,546
US Patent 8,895,546 was granted on November 25, 2014, to Amgen Inc. It covers methods related to erythropoietin (EPO) variants and compositions, primarily focusing on innovative EPO proteins with enhanced pharmacokinetic profiles and reduced immunogenicity. The patent claims encompass novel amino acid sequences, methods of production, and therapeutic applications.
Scope of the Patent Claims
The patent's claims delineate the boundaries of the intellectual property rights. Key elements include:
-
Protein Claims:
- Variants of erythropoietin with specific amino acid substitutions.
- EPO proteins that have certain glycosylation patterns.
- EPO that exhibits extended half-life or increased stability.
- Sequences set forth in specific peptide forms with modifications to improve activity or reduce immunogenicity.
-
Method Claims:
- Methods of producing these EPO variants using recombinant DNA technology.
- Methods for administering the EPO variants for treating anemia associated with chronic renal failure or chemotherapy.
- Assays for screening or characterizing such proteins.
-
Use and Composition Claims:
- Therapeutic compositions comprising the claimed EPO variants.
- Dosing regimens and formulation claims intended for clinical use.
The claims are predominantly composition of matter and method claims, with some dependent claims specifying particular sequence modifications, glycosylation sites, or methods.
Claim breadth allows for coverage of multiple EPO variants and their methods of production within broad parameters. The patent explicitly protects certain amino acid substitutions at critical sites known to affect stability and immunogenicity, notably at positions 24, 83, and 88.
Claims Analysis
-
Broadness:
- The patent claims include a genus of EPO variants with specific amino acid modifications, giving a broad scope.
- It encompasses both naturally occurring and synthesized variants, including glycosylation modifications.
- The use of generic language like "comprising" broadens the scope to include additional elements.
-
Limitations:
- Specific amino acid substitutions are detailed, such as substitutions at positions 24, 38, 78, 83, 88, and glycosylation sites.
- Some claims specify the modified EPO with enhanced half-life or reduced immunogenicity, which narrows focus toward specific desired properties.
-
Potential Challenges:
- Overlap with prior art exists around known EPO modifications, such as PEGylation or glycosylation enhancements.
- The patent's reliance on specific amino acid substitutions as distinguishing features could be circumscribed if similar modifications are known.
Patent Landscape and Prior Art
Related Patents and Applications:
- Amgen’s EPO patents:
- US Patent 5,547,933 (issued 1996) covers earlier forms of erythropoietin.
- US Patent 8,603,844 (2013) protects glycoengineering techniques for EPO variants.
- Johnson & Johnson and Roche have patents covering alternative EPO modifications, including PEGylated and hyperglycosylated forms.
- Generic biosimilar efforts:
- Several biosimilar developers, including Sandoz and Biocon, have sought to design EPO versions avoiding infringing on these patents.
- Patent landscapes also include patents for detailed glycosylation techniques, production cell lines, and delivery methods.
Patent Expiry and Litigation:
- The '546 patent expires in 2032, assuming maintenance fees are paid on time.
- The patent has been cited in patent litigations, often in patent infringement suits concerning biosimilar EPO products.
Freedom-to-Operate Considerations:
- Work arounds involve modifications outside claimed amino acid positions.
- Patent claims are strong around specific amino acid changes, especially at key glycosylation sites.
- Biosimilar candidates often seek to avoid overlap by selecting alternative sequence modifications or new glycosylation patterns.
Legal Strategies:
- Patent challengers often focus on non-infringing alternative glycosylation or production methods.
- In licensing negotiations, Amgen’s broad claims and early patent filings provide leverage.
Summary of Patent Landscape
| Patent/Document |
Key Focus |
Filing Date |
Expiry |
Relevance |
| US 8,895,546 |
EPO variants with amino acid substitutions |
2009 |
2032 |
Core patent for specific variants and methods |
| US 5,547,933 |
Original EPO protein |
1994 |
Expired |
Foundational for EPO patents |
| US 8,603,844 |
Glycoengineering techniques |
2012 |
2030 |
Related to glycosylation modifications |
| WO2018/222140 |
Biosimilar EPOs |
2018 |
2038 |
Biosimilar development, non-infringing alternatives |
Key Takeaways
- US Patent 8,895,546 claims an extensive class of EPO variants with specific amino acid and glycosylation modifications, covering therapeutic and manufacturing methods.
- Its breadth supports protection of numerous protein forms and formulations, with particular emphasis on stability and immunogenicity reduction.
- The patent landscape includes prior foundational patents and subsequent glycoengineering improvements; biosimilar developers target modifications outside the claimed amino acid sites.
- Patent expiry in 2032 may open opportunities for biosimilar entry, provided design-around strategies are employed.
- The patent’s strong claim scope may pose challenges for competitors attempting to develop similar formulations without infringement.
FAQs
1. What are the main amino acid modifications claimed in US 8,895,546?
The patent claims modifications primarily at amino acid positions 24, 38, 78, 83, and 88, which influence stability and immunogenicity.
2. How does the patent impact biosimilar development?
It restricts biosimilar EPO formulations that replicate the claimed amino acid sequences unless they employ non-infringing modifications or license the patents.
3. Are glycosylation patterns covered in the patent claims?
Yes. Specific glycosylation modifications and their impact on pharmacokinetics are included, notably with claims toward particular glycosylation sites.
4. How broad are the patent claims?
They cover a genus of protein variants with at least one of several amino acid substitutions, leading to broad coverage of multiple EPO modifications.
5. When does this patent expire, and what are the implications?
Expiration is projected for 2032, after which generic versions may enter the market pending legal and regulatory clearance.
References
[1] US Patent 8,895,546.
[2] US Patent 5,547,933.
[3] US Patent 8,603,844.
[4] WO2018/222140.
